Radioactive iodine (RAI) is used in the adjuvant setting for patients with high-risk characteristics such as tumor size >2 cm, positive margins, cervical lymph node metastases, microvascular invasion, or postoperative thyroglobulin levels > 1 ng/mL. The gene discussed is TG; the disease is neoplasm.